GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (STU:9U90) » Definitions » Total Liabilities

Unity Biotechnology (STU:9U90) Total Liabilities : €32.09 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Total Liabilities?

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 was €32.09 Mil.

Unity Biotechnology's quarterly Total Liabilities increased from Sep. 2023 (€30.98 Mil) to Dec. 2023 (€34.20 Mil) but then declined from Dec. 2023 (€34.20 Mil) to Mar. 2024 (€32.09 Mil).

Unity Biotechnology's annual Total Liabilities increased from Dec. 2021 (€57.65 Mil) to Dec. 2022 (€64.44 Mil) but then declined from Dec. 2022 (€64.44 Mil) to Dec. 2023 (€34.20 Mil).


Unity Biotechnology Total Liabilities Historical Data

The historical data trend for Unity Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Total Liabilities Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 27.46 60.37 57.65 64.44 34.20

Unity Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.96 47.63 30.98 34.20 32.09

Unity Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Unity Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.189+(21.585+5.423
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=34.20

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=60.238-26.041
=34.20

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.113+(20.798+4.174
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=32.09

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=54.154-22.069
=32.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unity Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (STU:9U90) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Unity Biotechnology (STU:9U90) Headlines

No Headlines